

### **HEALTHCARE MONTHLY**

**OCTOBER 2023** 

Our healthcare team architects market-defining outcomes for some of the most innovative medical device, life science and diagnostics, healthcare services and pharmaceutical companies in the world.

BioTech / Pharma **Healthcare Services** Life Sciences / Diagnostics



**Medical Devices** 

### **HEADLINE TRANSACTIONS**

ACOUIROR

ACQUISITION SYNOPSIS





- Permira Advisors LLP has entered a definitive agreement to acquire Ergomed plc (LON:ERGO)
- · Permira is a British private equity firm with ~\$80 billion AUM investing across the technology, consumer, healthcare and services sectors
- Ergomed is a British provider of clinical development, medical information and pharmacovigilance services to the pharmaceutical industry
- Total Consideration: \$886 million
- · Per Share Price Premium: 28%





- Boston Scientific Corporation (NYSE:BSX) has entered a definitive agreement to acquire Relievant Medsystems, Inc.
- Boston Scientific is a medical device company manufacturing and marketing equipment for interventional medical specialties including cardiology, radiology, oncology and neuromodulation for chronic pain
- Relievant Medsystems is a medical device company that developed and commercialized the Intracept® System, a minimally invasive outpatient procedure using nerve ablation to address common vertebrogenic lower back pain
- Total Consideration: \$850 million paid in cash







- Enovis Corporation (NYSE:ENOV) has entered a definitive agreement to acquire LimaCorporate, S.p.A., a portfolio company of EQT Partners, AB
- Enovis is a medical device company manufacturing and distributing orthotics, surgical hip & shoulder implants and equipment for postsurgery recovery, rehabilitation & pain management
- LimaCorporate is an Italian medical device company manufacturing and distributing standard and custom 3D-printed prosthetic knee, elbow & shoulder implants and surgical instruments
- Total Consideration: \$800 million consisting of \$700 million in cash and \$100 million in stock






- · Alfasigma S.p.A. has entered into a definitive merger agreement with Intercept Pharmaceuticals, Inc (NASD:ICPT)
- · Alfasigma is an Italian pharmaceutical company manufacturing and distributing prescription medications targeting therapeutic areas including gastrointestinal and primary care
- Intercept 
  ALFASIGMA

   Intercept is a biotechnology company developing and commercializing therapeutics targeting rare and serious liver diseases; its flagship product is Ocaliva® an FDA-approved second-line therapy for primary biliary cholangitis product is Ocaliva®, an FDA-approved second-line therapy for primary biliary cholangitis
  - Total Consideration: \$794 million paid in cash
  - · Per Share Price Premium: 82%




# HEALTHCARE GROWTH & VALUATION TRENDS


#### **Enterprise Value / LTM Revenue**




#### **Enterprise Value / LTM EBITDA**



#### LTM Revenue Growth




#### LTM Gross and EBITDA Margins\*



\*EBITDA Margins shown as the gray line.

#### **LTM Stock Price Index**





## SELECTED HEALTHCARE TRANSACTIONS


Target	Acquiror	BioTech / Pharma Transactions
Paratek Pharmaceuticals, Inc.	Novo Holdings A/S; Gurnet Point Capital, Ltd	Paratek is a commercial-stage biopharmaceutical company; its flagship products include NUZYRA®, an oral broad-spectrum antibiotic and SEYSARA®, an oral therapy for acne vulgaris Total Consideration: \$462 million
adivo, GmbH	Zoetis, Inc (NYSE:ZTS)	adivo is a German biotechnology company discovering and developing species-specific therapeutic antibodies for companion animals targeting treatment areas including oncology and inflammatory diseases
Applied Molecular Transport, Inc (NASD:AMTI)	Cyclo Therapeutics, Inc (NASD:CYTH)	AMT and Cyclo have entered an all-stock definitive merger agreement Cyclo is a clinical stage biotech company developing therapies for cholesterol transport diseases, Niemann-Pick Type-C and Alzheimer's AMT is a biopharmaceutical company developing molecular systems that facilitate active transport through the intestinal epithelial barrier
Target	Acquiror	Life Sci / Diagnostics Transactions
Pepceuticals, Ltd	Biosynth, AG (KKR & Co, Inc; Ampersand Capital Partners)	Pepceuticals is a Swedish life sciences company manufacturing custom & ready-made synthetic peptides, reagents and antibodies
Resolution Bioscience, Inc (Agilent Technologies, Inc)	Exact Sciences Corporation	Resolution Bioscience is engaged in the development of a non-invasive liquid biopsy platform
CIRION BioPharma Research, Inc	Cerba Healthcare, SASU (EQT Partners, AB)	CIRION is a Canadian contract research laboratory offering pharmacokinetic-pharmacodynamic (PKPD) analysis and immunogenicity testing in global clinical trials

#### Selected TM Capital Healthcare Experience









#### TM Capital's Healthcare Industry Contacts



James McLaren Managing Director jmclaren@tmcapital.com 212.809.1414



Michael Goldman Managing Director mgoldman@tmcapital.com 212.809.1419



John Dean Principal jdean@tmcapital.com 404.995.6234



Paul Smolevitz Managing Director psmolevitz@tmcapital.com 212.809.1416



Steve Hunter Managing Director, Sponsor Coverage shunter@tmcapital.com 404.995.6232

